BioLineRx Ltd.
BLRX
$4.24
-$0.33-7.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 255.00K | 11.75M | 4.94M | 5.39M | 6.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 255.00K | 11.75M | 4.94M | 5.39M | 6.86M |
| Cost of Revenue | 34.00K | 6.09M | 822.00K | 897.00K | 1.46M |
| Gross Profit | 221.00K | 5.66M | 4.12M | 4.50M | 5.40M |
| SG&A Expenses | 989.00K | 6.97M | 6.94M | 8.04M | 7.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.65M | 14.92M | 10.33M | 11.17M | 11.68M |
| Operating Income | -2.39M | -3.17M | -5.39M | -5.77M | -4.82M |
| Income Before Tax | 5.13M | -3.19M | -5.82M | 484.00K | -696.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.13M | -3.19M | -5.82M | 484.00K | -696.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.13M | -3.19M | -5.82M | 484.00K | -696.00K |
| EBIT | -2.39M | -3.17M | -5.39M | -5.77M | -4.82M |
| EBITDA | -2.23M | -1.93M | -4.55M | -5.30M | -3.93M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.22B | 1.31B | 1.20B | 1.20B | 1.09B |
| Average Diluted Shares Outstanding | 2.22B | 1.31B | 1.20B | 1.20B | 1.09B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |